According to Exelixis's latest financial reports the company has a price-to-book ratio of 3.09.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Year | P/B ratio | Change |
---|---|---|
2023-12-31 | 3.30 | 58.49% |
2022-12-31 | 2.08 | -20.53% |
2021-12-31 | 2.62 | -21.04% |
2020-12-31 | 3.31 | 4.35% |
2019-12-31 | 3.18 | -30.69% |
2018-12-31 | 4.58 | -85.48% |
2017-12-31 | 31.6 | -34.79% |
2016-12-31 | 48.4 | -630.03% |
2015-12-31 | -9.13 | 271.69% |
2014-12-31 | -2.46 | -114.38% |
2013-12-31 | 17.1 | 503.03% |
2012-12-31 | 2.83 | -60.01% |
2011-12-31 | 7.08 | -280.23% |
2010-12-31 | -3.93 | -19.11% |
2009-12-31 | -4.86 | -48.44% |
2008-12-31 | -9.42 | -189.13% |
2007-12-31 | 10.6 | 10.87% |
2006-12-31 | 9.53 | -30.47% |
2005-12-31 | 13.7 | -2.47% |
2004-12-31 | 14.1 | 351.72% |
2003-12-31 | 3.11 | 15.26% |
2002-12-31 | 2.70 |
Company | P/B ratio | differencediff. | Country |
---|---|---|---|
Johnson & Johnson JNJ | 5.12 | 65.92% | ๐บ๐ธ USA |
Pfizer PFE | 1.61 | -47.80% | ๐บ๐ธ USA |
Amgen AMGN | 23.2 | 652.93% | ๐บ๐ธ USA |
Sanofi SNY | 1.49 | -51.65% | ๐ซ๐ท France |
Merck MRK | 8.83 | 186.13% | ๐บ๐ธ USA |
Bristol-Myers Squibb BMY | 3.08 | -0.10% | ๐บ๐ธ USA |
GlaxoSmithKline GSK | 5.16 | 67.08% | ๐ฌ๐ง UK |
Curis CRIS | 4.34 | 40.50% | ๐บ๐ธ USA |
AVEO Oncology
AVEO | 18.1 | 485.76% | ๐บ๐ธ USA |